TransMedics Group, Inc. (TMDX)
NASDAQ: TMDX · Real-Time Price · USD
115.18
+0.21 (0.18%)
At close: Aug 26, 2025, 4:00 PM
115.00
-0.18 (-0.16%)
After-hours: Aug 26, 2025, 4:17 PM EDT
TransMedics Group Stock Forecast
Stock Price Forecast
The 8 analysts that cover TransMedics Group stock have a consensus rating of "Buy" and an average price target of $123, which forecasts a 6.79% increase in the stock price over the next year. The lowest target is $75 and the highest is $150.
Price Target: $123 (+6.79%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for TransMedics Group stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 4 | 4 | 4 | 4 | 4 | 3 |
Hold | 3 | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 10 | 10 | 10 | 10 | 10 | 9 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Aug 25, 2025 |
Morgan Stanley | Morgan Stanley | Hold Maintains $115 → $123 | Hold | Maintains | $115 → $123 | +6.79% | Aug 1, 2025 |
Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $129 → $142 | Strong Buy | Maintains | $129 → $142 | +23.29% | Jul 15, 2025 |
Oppenheimer | Oppenheimer | Buy Maintains $130 → $150 | Buy | Maintains | $130 → $150 | +30.23% | Jun 17, 2025 |
Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 17, 2025 |
Financial Forecast
Revenue This Year
613.13M
from 441.54M
Increased by 38.86%
Revenue Next Year
740.62M
from 613.13M
Increased by 20.79%
EPS This Year
2.41
from 1.01
Increased by 138.21%
EPS Next Year
2.79
from 2.41
Increased by 15.93%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 635.3M | 797.2M | |||
Avg | 613.1M | 740.6M | |||
Low | 585.2M | 673.7M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 43.9% | 30.0% | |||
Avg | 38.9% | 20.8% | |||
Low | 32.5% | 9.9% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | 2.71 | 3.41 | |
Avg | 2.41 | 2.79 | |
Low | 2.05 | 2.16 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | 168.2% | 41.8% | |
Avg | 138.2% | 15.9% | |
Low | 102.8% | -10.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.